Security
Caris Life Sciences, Inc. Common Stock · CAI
CAINASDAQCommon stockCurrentCIK 2019410Updated Oct 6, 2026
CAI price & chart
Loading TradingView…
NASDAQ:CAI on TradingView ↗About the company
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| AssetsUSD | 984,571,000Source | — | 1,229,620,000Source | 955,058,000Source | — | 1,162,388,000Source | — | 1,125,663,000Source | 343,734,000Source |
| Property, Plant and Equipment, NetUSD | 63,997,000Source | — | 95,716,000Source | 61,315,000Source | — | 82,669,000Source | — | 63,170,000Source | 67,817,000Source |
| GoodwillUSD | 19,344,000Source | — | 19,344,000Source | 19,344,000Source | — | 19,344,000Source | — | 19,344,000Source | 19,344,000Source |
| Current assets: | |||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 753,221,000Source | — | — | 718,934,000Source | — | 819,901,000Source | 31,201,000Source | 796,274,000Source | 63,950,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 26,697,000Source | — | 116,888,000Source | 50,889,000Source | — | 90,517,000Source | — | 112,140,000Source | 88,244,000Source |
| Assets, CurrentUSD | 854,245,000Source | — | 1,057,828,000Source | 833,319,000Source | — | 1,014,180,000Source | — | 997,800,000Source | 215,729,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 21,234,000Source | — | 24,034,000Source | 19,124,000Source | — | 23,912,000Source | — | 21,941,000Source | 20,270,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | 39,848,000Source | 34,950,000Source |
| Other Assets, NoncurrentUSD | 46,985,000Source | — | 56,732,000Source | 41,080,000Source | — | 46,195,000Source | — | 45,349,000Source | 40,844,000Source |
| LIABILITIES AND EQUITY | |||||||||
| LiabilitiesUSD | 506,207,000Source | — | 637,886,000Source | 502,154,000Source | — | 568,898,000Source | — | 548,356,000Source | 620,921,000Source |
| Stockholders’ equity: | |||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 283,000Source | — | 283,000Source | 282,000Source | — | 284,000Source | — | 283,000Source | 38,000Source |
| Additional Paid in CapitalUSD | 3,124,943,000Source | — | 3,140,805,000Source | 3,123,888,000Source | — | 3,158,455,000Source | — | 3,141,720,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -2,630,693,000Source | — | -2,549,883,000Source | -2,655,018,000Source | — | -2,549,246,000Source | — | -2,548,736,000Source | -2,472,300,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 748,000Source | — | 529,000Source | 669,000Source | — | 893,000Source | — | 936,000Source | 210,000Source |
| Stockholders' Equity Attributable to ParentUSD | 478,364,000Source | -2,441,953,000Source | 591,734,000Source | 452,904,000Source | -2,359,590,000Source | 593,490,000Source | -2,599,865,000Source | 577,307,000Source | -2,498,838,000Source |
| Liabilities and EquityUSD | 984,571,000Source | — | 1,229,620,000Source | 955,058,000Source | — | 1,162,388,000Source | — | 1,125,663,000Source | 343,734,000Source |
| Current liabilities: | |||||||||
| Liabilities, CurrentUSD | 86,030,000Source | — | 191,437,000Source | 90,180,000Source | — | 143,896,000Source | — | 127,145,000Source | 165,423,000Source |
| Operating Lease, Liability, CurrentUSD | 6,450,000Source | — | 6,367,000Source | 7,291,000Source | — | 5,836,000Source | — | 6,359,000Source | 6,080,000Source |
| Accounts Payable, CurrentUSD | 28,999,000Source | — | 85,986,000Source | 28,728,000Source | — | 69,802,000Source | — | 39,206,000Source | 27,791,000Source |
| Operating Lease, Liability, NoncurrentUSD | 43,828,000Source | — | 52,884,000Source | 37,983,000Source | — | 43,547,000Source | — | 42,335,000Source | 38,651,000Source |
| Other Liabilities, NoncurrentUSD | 43,881,000Source | — | 53,476,000Source | 38,363,000Source | — | 43,600,000Source | — | 42,388,000Source | 44,418,000Source |
| Additional Financial Items | |||||||||
| Accrued Liabilities, CurrentUSD | 56,867,000Source | — | 105,273,000Source | 61,357,000Source | — | 73,921,000Source | — | 87,770,000Source | 77,542,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | 0Source | 0Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | 384,436,000Source | 0Source |
| Long-term Debt, Excluding Current Maturities | —Source | — | —Source | —Source | — | —Source | — | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | 164,000Source | — | 178,000Source | 95,000Source | — | 173,000Source | — | 169,000Source | 60,090,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 376,296,000Source | — | 392,973,000Source | 373,611,000Source | — | 381,402,000Source | — | 378,823,000Source | 319,438,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 4,900,000Source | 10,500,000Source | 6,500,000Source | 6,400,000Source | 5,065,000Source | 7,045,000Source | 22,615,000Source | 48,913,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 15,872,000Source | 14,691,000Source | 70,006,000Source | 18,643,000Source |
| Changes in operating assets and liabilities: | ||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -21,623,000Source | -7,913,000Source | 29,789,000Source | 33,816,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 16,371,000Source | -1,739,000Source | 11,035,000Source | -226,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 32,876,000Source | -31,338,000Source | 83,155,000Source | -245,199,000Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -10,342,000Source | -2,689,000Source | -16,260,000Source | 52,932,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 10,342,000Source | 2,689,000Source | 16,260,000Source | 8,444,000Source |
| Cash flows from financing activities: | ||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 56,000Source | 0Source | 18,551,000Source | 0Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 0Source | 22,000Source | 113,000Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 824,000Source | 1,285,000Source | 664,989,000Source | 200,292,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 23,348,000Source | -32,738,000Source | 732,014,000Source | 8,021,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 756,982,000Source | — | — | 722,687,000Source | — | — | 800,042,000Source | 68,028,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 43,520,000Source | 49,017,000Source |
| Additional Financial Items | ||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 13,655,000Source | 4,723,000Source | 22,219,000Source | 28,293,000Source | 15,872,000Source | 14,691,000Source | 70,006,000Source | 18,643,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | 384,436,000Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | -25,232,000Source | -17,930,000Source | — | — | -19,895,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 51,973,000Source | 40,852,000Source | 66,548,000Source | 64,367,000Source | 59,708,000Source | 52,119,000Source | 224,965,000Source | 169,386,000Source |
| GoodwillUSD | — | — | 19,344,000Source | — | 19,344,000Source | 19,344,000Source | 19,344,000Source | — | 19,344,000Source | 19,344,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 23,000Source | 0Source | -134,000Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 13,507,000Source | 13,799,000Source | 9,228,000Source | 19,208,000Source | 12,809,000Source | 12,782,000Source | 56,853,000Source | 50,025,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 2,600,000Source | 4,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 24,325,000Source | -67,729,000Source | -637,000Source | -71,790,000Source | -510,000Source | -102,581,000Source | -68,088,000Source | -281,890,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 24,325,000Source | -92,390,000Source | -637,000Source | -517,197,000Source | -510,000Source | -127,043,000Source | -537,957,000Source | -378,257,000Source |
| Nonoperating Income (Expense)USD | — | — | -8,317,000Source | -6,887,000Source | -27,540,000Source | -53,801,000Source | -5,926,000Source | -44,629,000Source | -113,201,000Source | -24,768,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -89,000Source | 37,000Source | -25,131,000Source | -18,341,000Source | 49,000Source | -17,000Source | -20,560,000Source | -349,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | 0Source | 61,376,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 920,000Source | 1,434,000Source | 7,637,000Source | 1,530,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 216,833,000Source | 101,620,000Source | 263,712,000Source | 181,398,000Source | 216,174,000Source | 120,915,000Source | 812,033,000Source | 412,260,000Source |
| Operating Income (Loss)USD | — | — | 32,642,000Source | -60,842,000Source | 26,926,000Source | -17,989,000Source | 5,282,000Source | -57,952,000Source | 45,113,000Source | -257,122,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -89,000Source | 37,000Source | -25,131,000Source | -18,341,000Source | 49,000Source | -17,000Source | -20,560,000Source | -349,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 24,325,000Source | -67,729,000Source | -614,000Source | -71,790,000Source | -644,000Source | -102,581,000Source | -68,088,000Source | -281,890,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 23,000Source | 0Source | -134,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 24,325,000Source | -67,729,000Source | -637,000Source | -71,790,000Source | -510,000Source | -102,581,000Source | -68,088,000Source | -281,890,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.09Source | -2.59Source | 0Source | -7.97Source | 0Source | -3.57Source | -3.22Source | -10.66Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.08Source | -2.59Source | 0Source | -7.97Source | 0Source | -3.57Source | -3.22Source | -10.66Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 282,099,073Source | 35,643,589Source | 282,888,610Source | 64,918,988Source | 282,562,013Source | 35,623,042Source | 167,205,616Source | 35,496,832Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 297,211,838Source | 35,643,589Source | 282,888,610Source | 64,918,988Source | 282,562,013Source | 35,623,042Source | 167,205,616Source | 35,496,832Source |
| Interest Expense (non-operating)USD | — | — | 13,507,000Source | 13,799,000Source | 9,228,000Source | 19,208,000Source | 12,809,000Source | 12,782,000Source | 56,853,000Source | 50,025,000Source |
| Additional Financial Items | ||||||||||
| Costs and ExpensesUSD | — | — | 184,191,000Source | 162,462,000Source | 236,786,000Source | 199,387,000Source | 210,892,000Source | 178,867,000Source | 766,920,000Source | 669,382,000Source |
| General and Administrative ExpenseUSD | — | — | 51,973,000Source | 40,852,000Source | 66,548,000Source | 64,367,000Source | 59,708,000Source | 52,119,000Source | 224,965,000Source | 169,386,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -70,469,000Source | -283,720,000Source |
| Interest Expense, DebtUSD | — | — | 13,499,000Source | 13,790,000Source | 9,216,000Source | 19,201,000Source | 12,796,000Source | 12,774,000Source | 56,814,000Source | 49,990,000Source |
| Interest Income, OtherUSD | — | — | 7,360,000Source | 1,744,000Source | 6,819,000Source | 1,618,000Source | 6,834,000Source | 503,000Source | 16,497,000Source | 7,122,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 24,325,000Source | -92,390,000Source | -637,000Source | -517,197,000Source | -510,000Source | -127,043,000Source | -537,957,000Source | -378,257,000Source |
| Nonoperating Income (Expense)USD | — | — | -8,317,000Source | -6,887,000Source | -27,540,000Source | -53,801,000Source | -5,926,000Source | -44,629,000Source | -113,201,000Source | -24,768,000Source |
| Research and Development ExpenseUSD | — | — | 21,624,000Source | 27,644,000Source | 32,358,000Source | 25,047,000Source | 31,315,000Source | 23,066,000Source | 101,584,000Source | 113,916,000Source |
| Selling and Marketing ExpenseUSD | — | — | 41,267,000Source | 36,758,000Source | 53,764,000Source | 42,260,000Source | 45,043,000Source | 39,829,000Source | 167,506,000Source | 152,602,000Source |
Offerings
Registration 333-287551
- Gross proceeds
- 494117652.0
- Net proceeds
- 459529416.36
- Deal price
- 21.0
- Shares
- 23529412
- Offering price
- $21.00
- Ticker
- CAI
Filing attachments
cai_ex99-1.htm · 8-K · 2026-08-05
EX-99.1 2 cai_ex99-1.htm EX-99.1 Document Exhibit 99.1 Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28% IRVING, T…
Read attachment ↗cai_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 cai_ex99-1.htm EX-99.1 Document Exhibit 99.1 Caris Life Sciences Reports First Quarter 2026 Financial Results Revenue growth of 79% driven by strong performance in molecular profiling services IRVING, Texas, May 07, 2026 - Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights • Reported…
Read attachment ↗cai_ex99-1.htm · 8-K · 2026-02-26
EX-99.1 2 cai_ex99-1.htm EX-99.1 Document Exhibit 99.1 Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Full year revenue growth of 97% driven by strong performance in molecular profiling services Expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion IRVING, Texas, February 26, 2026 - Caris Life Sciences, Inc. (NASDAQ: CAI), a leading, patient centric, next-generation AI TechBio company and precision m…
Read attachment ↗cai_ex99-1.htm · 8-K · 2026-01-12
EX-99.1 2 cai_ex99-1.htm EX-99.1 Document Exhibit 99.1 Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services IRVING, Texas, January 12, 2026 - Caris Life Sciences, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced preliminary, unaudited financial results for the fourth quar…
Read attachment ↗cai_ex99-1.htm · 8-K · 2025-11-05
EX-99.1 2 cai_ex99-1.htm EX-99.1 Document Exhibit 99.1 Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $720 to $730 million, representing year-over-year growth of 75-77% IRVING, Texas, November 05, 2025 - Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today report…
Read attachment ↗cai_ex99-1.htm · 8-K · 2025-08-12
EX-99.1 2 cai_ex99-1.htm EX-99.1 Document Exhibit 99.1 Caris Life Sciences Reports Second Quarter 2025 Financial Results IRVING, Texas, August 12, 2025 - Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights • Reported total revenue of $181.4 million, an increase of 81.3% over the corresponding prior year period. • Completed 5…
Read attachment ↗